RNS Number : 4687E

HealthBeacon PLC

30 June 2023

30 June 2023

HealthBeacon plc

Annual Report 2022 and Commercial Update

Dublin, HealthBeacon plc ("HealthBeacon" or "the Company"), today announces the publication of its Annual Report for the year ended 31 December 2022.  

Copies of the Annual Report are available online at https://healthbeacon.com/financial-reports-and-documents/.

In 2022, HealthBeacon was very successful in acquiring large US Specialty Pharmacies, Global Pharmaceutical Manufacturers and Clinical Groups that will drive rapid scaling of its US business over the coming years.  

HealthBeacon is pleased to confirm the launch of its Accredo specialty pharmacy rollout with a blockbuster drug in July 2023, as well as, the activation of its Remote Therapeutic Monitoring Platform to support Medicare patients in eligible therapeutic conditions. This comes on the back of the transformative supply chain partnership with Hamilton Beach Brands announced on June 19^th to support these large scale rollouts. 

ENDS

Enquiries:

HealthBeacon:

Jim Joyce                                                                        investorrelations@healthbeacon.com

Lar Malone

Goodbody (Euronext Listing Sponsor and Broker):

David Kearney                                                                                            +353 (1) 667 0420

Stephen Kane

Drury (Public Relations):

Cathal Barry                                                                                          +353 (0) 87 227 9281

Gavin McLoughlin                                                                                 +353 (0) 86 035 3749

About HealthBeacon:

Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company that

develops smart tools for managing medications for patients in the home.

The HealthBeacon Injection Care Management System tracks adherence and persistence with medication schedules through the provision of medication management reminders, safe and sustainable sharps disposal devices, educational tools, and artificial intelligence (AI) driven data analytics.

Peer reviewed evidence supports a 19% improvement in therapy persistence by patients and up to 26% improvement in adherence to therapy, which improves clinical outcomes and significantly improves efficiency in health systems.

The Company has expanded its offering to growth management with the launch of its

integrated Smart Scale and oral adherence with the launch of HB Wave which integrates

with its existing technology.

The Company operates across Europe, North America and the United Kingdom and employs more than 70 people and has obtained more than 30 design and utility patents.

The Company's mission is to become the world's leading digital therapeutics platform for patients managing medications in the home.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ISEDBGDLSUDDGXC